Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.41 |
| ▸ | CCND1 | P24385 | 8/20 | 0.40 |
| ▸ | CDK2 | P24941 | 8/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.40 |
| ▸ | CDK4 | P11802 | 3/20 | 0.40 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.40 |
| ▸ | SIK1 | P57059 | 1/20 | 0.40 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.40 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084454 | 0.90 | LCK (0.49) | LCKMAPK14TNK2ABL1PAK1 | |
| SCHEMBL4090848 | 0.89 | MAPK14 (0.63) | LCKMAPK14ABL1FGFR1 | |
| SCHEMBL4091218 | 0.87 | MAPK14 (0.46) | LCKMAPK14TNK2ABL1PAK1 | |
| SCHEMBL4090415 | 0.84 | MAPK14 (0.46) | LCKMAPK14TNK2ABL1PAK1 | |
| SCHEMBL4094294 | 0.84 | MAPK14 (0.64) | LCKMAPK14ABL1PAK1FGFR1 | |
| SCHEMBL4084379 | 0.84 | LCK (0.56) | LCKMAPK14TNK2ABL1CCND1 | |
| SCHEMBL4094645 | 0.83 | LCK (0.49) | LCKMAPK14TNK2ABL1PAK1 | |
| SCHEMBL13849294 | 0.82 | LCK (0.54) | LCKMAPK14TNK2ABL1PAK1 | |
| SCHEMBL4088401 | 0.82 | LCK (0.45) | LCKMAPK14TNK2ABL1PAK1 | |
| SCHEMBL4084246 | 0.82 | LCK (0.42) | LCKMAPK14TNK2ABL1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | claimed |
| EP-1831215-A1 | PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-09-12 | — | — | EP | claimed |
| WO-2006056863-A1 | PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-01 | — | — | WO | claimed |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1831215-A1 | PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006056863-A1 | PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | TLR1, TPMT, NOD1 | LCK 568/4885MAPK14 3185/4885TNK2 1374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.